|Year : 2011 | Volume
| Issue : 4 | Page : 459-462
Impact of Gleason pattern up gradation after radical prostatectomy for carcinoma prostate patients with low biopsy score (≤ 6)
Jagdeesh N Kulkarni, Rohan S Valsangkar, Yogesh R Jadhav, Dayal Partap Singh
Department of Urology, Bombay Hospital Institute of Medical Sciences, Mumbai, Maharashtra, India
|Date of Web Publication||19-Jan-2012|
Jagdeesh N Kulkarni
Atharva, 2nd Floor, Lake Boulevard, Hiranandani Gardens, Powai, Mumbai, Maharashtra
Source of Support: None, Conflict of Interest: None
Context: Biopsy Gleason score (b-GS) is often different from the Gleason score obtained after analysis of radical prostatectomy (RP) specimen (rp-GS). Upgradation has an important implication in decision making for cancer prostate management, and is the focus of this study.
Aim: To evaluate Gleason score upgradation after radical prostatectomy with low biopsy score (≤ 6) and its correlation to pathological findings and outcome.
Settings and Design: This was a retrospective analysis of 257 cases of prostate cancer patients with initial b-GS ≤ 6, over a period of 14 years.
Materials and Methods: Data were divided into two groups according to (rp- GS) as 1) Group A (n=151; rp-GS ≤ 6 ) 2) and Group B(n=106; rp-GS ≥7). Both groups were compared in terms of the following: 1) preoperative variables e.g. age, PSA, transurethral resection of prostate (TURP) status, clinical T stage; 2) pathological features - rp GS, pathological stage (pT), capsular penetration, cut margin, seminal vesicle and lymph node status; 3) biochemical recurrence, overall and cancer specific mortality.
Statistical Analysis Used: Student's t test and Chi-square test.
Results: Group B had worse pathological features, except lymph node invasion, and they received significantly more adjuvant hormonal/local radiotherapy and had higher recurrence rate. However, the overall and cancer-specific mortality were similar in both the groups.
Conclusions: b-GS upgradation after radical prostatectomy is frequent and correlates with adverse pathological features, higher use of adjuvant therapy and higher recurrence rate. In Group B, adjuvant therapy delays the biochemical or clinical relapse and controls mortality in short-term follow up. Group A had favorable pathological findings and less recurrence rate.
Keywords: Gleason score up gradation, low biopsy Gleason score (≤ 6), pathology, prostate cancer, radical prostatectomy, seven-year survival
|How to cite this article:|
Kulkarni JN, Valsangkar RS, Jadhav YR, Singh DP. Impact of Gleason pattern up gradation after radical prostatectomy for carcinoma prostate patients with low biopsy score (≤ 6). J Can Res Ther 2011;7:459-62
|How to cite this URL:|
Kulkarni JN, Valsangkar RS, Jadhav YR, Singh DP. Impact of Gleason pattern up gradation after radical prostatectomy for carcinoma prostate patients with low biopsy score (≤ 6). J Can Res Ther [serial online] 2011 [cited 2020 May 30];7:459-62. Available from: http://www.cancerjournal.net/text.asp?2011/7/4/459/92021
| > Introduction|| |
Biopsy Gleason score (b-GS) is an important variable for decision making during the treatment of clinically localized prostate cancer (CaP) and outcome prediction. However, the initial low b-GS (≤ 6) is often upgraded to higher Gleason score at the radical prostatectomy specimen (rp- GS).  Further the impact of this error (upgradation) on tumor behavior and survival is unclear and becomes specially relevant before advising surveillance or wait and watch policy. Some authors have reported this clinical setting and suggested refinements in biopsy analysis and improved statistical methods to circumvent this problem of under scoring. ,
We herein report our experience of radical prostatectomy in 257 patients with b-GS ≤ 6. Analysis included comparison of the clinical preoperative variables, pathological features, recurrence pattern and outcome statistics in tumors that showed rp-GS≤ 6 (Group A) and rp-GS ≥ 7 (Group B).
| > Materials and Methods|| |
A total of 428 patients underwent open radical retro pubic prostatectomies by the first author over a period of 14 years from January 1996 to December 2009. Majority of the patients were referred to us after the diagnosis of CaP was made on prostate biopsy (TRUS guided or post TURP) elsewhere. Biopsy protocol was widely variable ranging from 4 core biopsy in the earlier years of the study to a more recently 12 core biopsy. From the data base, 257 patients with biopsy GS ≤6 and minimum follow up of 18 months were selected for retrospective analysis, after excluding the cases who had received prior hormonal therapy (which can change the pathological features) and patients with tumor vanishing syndrome (zero rp-GS). Preoperative biopsy and post-operative RP pathology review were done by the same pathologist. Adjuvant radiotherapy, hormone therapy either singly or in combination were given depending on the pathological findings. After RP, follow up was with PSA estimation three monthly till one year, and six monthly thereafter. A PSA value of > 0.2 ng/ml was taken as an indicator of biochemical recurrence (BCR). The patients with BCR or clinical relapse were investigated with radiological imaging (MR) and bone scan to localize the site of recurrence (local or distant) and offered hormonal therapy and local radiotherapy.
For the purpose of analysis, the data were divided into two groups depending on radical prostatectomy RP Gleason score (rp-GS) into the following: 1) Group A (n=151) (rp-GS ≤6) and 2) Group B (n=106) (rp-GS≥7) and compared in terms of clinical, pathological and prognostic variables: 1) preoperative clinical variables e.g. age, baseline PSA level, clinical stage (T), TURP status; 2) pathological findings : rp- GS, pathological stage (non-organ confined-pT3a and pT3b vs. organ confined: pT2a,b,c), capsular penetration, seminal vesicle invasion, cut margin status and lymph node status; 3) survival: biochemical recurrence rate, overall mortality rate and cancer specific mortality rate. The data were censored at seven year (84 months) for the survival analysis. The data were analyzed using SPSS (Statistical Package for Social Sciences) 14 software and statistical analysis included Student's t test and Chi-square test.
| > Results|| |
Mean age in our series was 63.4 years, mean PSA was 17.1 ng/ml and 78(30%) had prior TURP. All 257 patients had preoperative b-GS ≤ 6 with mean b-GS 5.5, and standard deviation (SD) 0.78, while radical prostatectomy specimen showed mean rp-GS of 6.3(SD 1.05). This difference from mean b-GS was statistically significant at P<0.05 using the Student's t test. Further, final rp-GS was ≤ 6 in 58.7% (n=151), 7 in 86 (33.4%) and GS 8-10 in 20(7.7%) cases [Table 1].
|Table 1: Pre-operative variables, histopathological features and outcome analysis of Groups A and B|
Click here to view
Group A had 151 patients and Group B had 106 patients. Only one preoperative variable i.e. clinical stage (T) was statistically significant across both groups. The number of T1 cases was higher in Group A while T2 cases were higher in Group B. Further, Group B had worse pathological findings and higher positive margin rate. Although the number of patients with positive nodes were more in Group B, the difference was not statistically significant. Moreover, from Group A, only 31(20.5%) patients received hormonal therapy, radiation therapy or both in follow up. This adjuvant treatment rate was significantly different from that required in 47(44.3%) patients in Group B (Chi-square test, P<0.0001). Similarly the outcome analysis showed higher biochemical relapses in group B; however, overall and cancer specific mortality were similar in both the groups. Lastly when mean follow up (post operative) PSA levels (Y axis) were plotted against the follow up period (time on X axis) as shown in [Figure 1], Group B had statistically significant higher mean PSA levels in comparison to Group A, indicating ensuing biochemical relapse.
|Figure 1: Follow up mean PSA trend in Groups A and B. PSA (on Y axis) against follow up time (on X axis)|
Click here to view
| > Discussion|| |
Currently, worldwide, majority of the CaP are diagnosed in low stage and favorable tumor grade (GS 6). For the past two decades, upgradation of biopsy GS (b-GS) after RP has been quite a frequent phenomenon (ranging from 32-73%).  Hence consensus was reached that low-grade (grade 2 to 4) cancers should rarely be diagnosed on needle biopsy.  Thus, GS 2-5 have virtually disappeared and GS 6 is the most common GS being reported now and with some chance of upgradation.
Recently, we reported our experience of open radical prostatectomy spanning over decade and found that after 2002, there has been a rise in the cases of radical prostatectomies.  From the same cohort of 428 patients, 257 had biopsy Gleason score (b GS≤ 6) ranging from 2 to 6, and analysis of these patients forms the basis of the report. As described in the "results" section, we found 41.2% patients had upgradation after analysis of RP specimen in our series. Of the various explanations offered for the upgradation of b-GS to higher rp-GS, inherent sampling error associated with prostate biopsy, multi focal nature of CaP and difference in the interpretation of the slides by two pathologists appear to be logical.  However, expertise of the pathologist can also be a factor in the prediction of upgradation.  Further even intra observer variation can be as high as 50%  and location of tumor can influence the pathology findings e.g. transitional zone tumors tend to have poor concordance.  Tumor heterogeneity is another factor, with heterogeneous tumors showing twice the upgradation rate as compared to homogeneous tumors. In our series, many patients had biopsies elsewhere and hence we tried to review them by a single pathologist to minimize pathological error.
Baseline PSA level did not help us in predicting the upgradation, unlike as reported by others. ,,,, We believe that previous TURP (30% in our study), which reduces the PSA at presentation, must have contributed to the poor correlation. Clinical stage (T) has been accurate in predicting the upgradation of GS in some series  including ours; but a few series have found clinical stage to be unreliable. 
Newer refinements in biopsy techniques and detailed pathological reporting of cancer (number of cores, length of each core, percentage of cancer in each core and total number of positive cores) and identification of tertiary score have shown salutary effect in predicting the upgradation of the b-GS. ,, The presence of prostatic intraepithelial neoplasia and perineural invasion were also found to be predictive of upgradation in one series. 
The question whether it is necessary to predict upgradation of b-GS in low Gleason score setting is very crucial. As discussed below, upgradation has a very important implication in the management of CaP. Further it is well known that rp-GS is a better predictor of biochemical recurrence free rate than b-GS. Review of the literature shows it is essential to rule out Gleason score ≥7 that is identification of primary or secondary score of 4 which necessitates the change in therapy.  Watchful waiting or active surveillance decision depends on b-GS and cancer volume among other factors. If a decision of active surveillance/conservative management is taken, a repeat saturation biopsy should be considered as even a repeat sextant biopsy decreases upgradation.  Discussion with the patient about the rp-GS being possibly higher than b-GS is also very important. Further radical prostatectomy for GS 7 needs additional pelvic lymphadenectomy as compared to GS 6.  Also higher incidence of non organ confined disease makes nerve sparing an inappropriate or technically difficult choice. Conversely, if radiotherapy is chosen as the primary modality, GS 7 cases need additional hormonal therapy as compared to GS 6. If brachytherapy is chosen as the primary modality, GS 7 cases need additional external beam radiation as compared to GS 6 cases who need only brachytherapy. 
In our study, upgradation was associated with greater capsular penetration rate, seminal vesicle invasion, and positive cut margin status, similar to other studies.  These histopathological features necessitated additional adjuvant radiotherapy and hormonal therapy. Moreover, these features are associated with greater risk of biochemical failure after radical prostatectomy as reflected in our series. Further, upgradation can influence the interpretation of the prognosis of CaP. If non-surgical therapy is chosen, a bias is introduced in comparison of surgical and non-surgical modalities favoring the surgical arm, as radiation group is a mixed group of both unfavorable and favorable cases.  Some studies claim that cases which are upgraded have more favorable outcome as compared to cases diagnosed with same b-GS on preoperative biopsy, e.g. cases with b-GS 6 and rp-GS 7 may have better prognosis than b-GS 7 and rp-GS 7 cases. 
Although upgraded group had higher biochemical recurrence rate and a trend of higher mean PSA in follow up in our series, cancer specific mortality was similar in both the groups unlike other studies.  This phenomenon may be due to relatively short follow-up period (seven year), during which adjuvant therapy must have had impact in delaying the progression. A longer follow up may reveal a difference across cancer-specific mortality, as earlier biochemical progression is generally associated with increased risk of cancer specific mortality.  Another explanation for similar mortality statistics is that, there is only a marginal difference in lymph node invasion rate in both the groups, unlike other pathological features.
Our series being retrospective in nature and spanning over decade has limitations in using the clinical parameters like PSA and clinical T staging methods which were still evolving in major part of the period. Further, one third cases had prior TURP added to the difficulties in staging and base line PSA levels. Cancer volume and other factors could not be ascertained till recently as majority had biopsies done elsewhere and not well standardized. Despite all the limitations, our series shows statistical impact in predicting the poor pathological features in upgraded group and identified the patients for adjuvant therapy.
In conclusion, our series proves that Gleason score upgradation after radical prostatectomy is frequent, and is associated with worse pathological features which translate into higher rates of post RP adjuvant hormonal or radiotherapy. Also upgradation is associated with higher biochemical recurrence rate which may lead to higher cancer-specific mortality in long-term follow up. Concordance of b-GS and rp-GS with initial low b-GS, however, points to a favorable pathological picture along with less need for adjuvant treatment and less biochemical recurrence rate. Our study further underscores the need of refinement of prostate biopsy technique and analysis along with the use of improved statistical methods so as to minimize the difference between biopsy Gleason score and the radical prostatectomy Gleason score.
| > References|| |
|1.||Chun FK, Steuber T, Erbersdobler A, Currlin E, Walz J, Schlomm T, et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006;49:820-6. |
|2.||D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995;154:131-8. |
|3.||Müntener M, Epstein JI, Hernandez DJ, Gonzalgo ML, Mangold L, Humphreys E, et al. Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 2008;53:767-75; discussion 775-6. |
|4.||Epstein JI. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: A diagnosis that should not be made. Am J Surg Pathol 2000;24:477-8. |
|5.||Kulkarni JN, Singh DP, Bansal S, Makkar M, Valsangkar R, Siddaiah AT, et al. Retropubic radical prostatectomy: Clinicopathological observations and outcome analysis of 428 consecutive patients. Indian J Urol 2011;27:337-44. |
|6.||Sooriakumaran P, Lovell DP, Henderson A, Denham P, Langley SE, Laing RW. Gleason scoring varies among pathologists and this affects clinical risk in patients with prostate cancer. Clin Oncol (R Coll Radiol) 2005;17:655-8. |
|7.||Kulkarni GS, Lockwood G, Evans A, Toi A, Trachtenberg J, Jewett MA, et al. Clinical predictors of Gleason score upgrading: Implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer 2007;109:2432-8. |
|8.||Gleason DF. Histologic grading of prostate cancer: A perspective. Hum Pathol 1992;23:273-9. |
|9.||Augustin H, Erbersdobler A, Graefen M, Jaekel T, Haese A, Huland H, et al. Differences in biopsy features between prostate cancers located in the transition and peripheral zone. BJU Int 2003;91:477-81. |
|10.||Moussa AS, Li J, Soriano M, Klein EA, Dong F, Jones JS. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int 2009;103:43-8. |
|11.||Kojima M, Troncoso P, Babaian RJ. Use of prostate specific antigen and tumor volume in predicting needle biopsy grading error. Urology 1995;45:807-12. |
|12.||Nayyar R, Singh P, Gupta NP, Hemal AK, Dogra PN, Seth A, et al. Upgrading of Gleason score on radical prostatectomy specimen compared to the pre-operative needle core biopsy: An Indian experience. Indian J Urol 2010;26:56-9. |
|13.||Hong SK, Han BK, Lee ST, Kim SS, Min KE, Jeong SJ, et al. Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy. World J Urol 2009;27:271-6. |
|14.||Gofrit ON, Zorn KC, Taxy JB, Lin S, Zagaja GP, Steinberg GD, et al. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer. J Urol 2007;178:1925-8. |
|15.||Moon SJ, Park SY, Lee TY. Predictive factors of Gleason score upgrading in localized and locally advanced prostate cancer diagnosed by prostate biopsy. Korean J Urol 2010;51:677-82. |
|16.||Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr, et al. Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: Results from the SEARCH database. J Urol 2008;179:523-7. |
|17.||Sved PD, Gomez P, Manoharan M, Kim SS, Soloway MS. Limitations of biopsy Gleason grade: Implications for counselling patients with biopsy Gleason score 6 prostate cancer. J Urol 2004;172:98-102. |
|18.||Fleshner NE, Cookson MS, Soloway SM, Fair WR. Repeat transrectal ultrasound-guided prostate biopsy: A strategy to improve the reliability of needle biopsy grading in patients with well-differentiated prostate cancer. Urology. 1998;52:659-62. |
|19.||Conrad S, Graefen M, Pichlmeier U, Henke RP, Erbersdobler A, Hammerer PG, et al. Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. J Urol 2002;167:521-5. |
|20.||Scherr D, Swindle PW, Scardino PT. National Comprehensive Cancer Network. National Comprehensive Cancer Network. Guidelines for the management of prostate cancer. Urology 2003;61:14-24. |
|21.||Djavan B, Kadesky K, Klopukh B, Marberger M, Roehrborn CG. Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol 1998;33:261-70. |
|22.||Pinthus JH, Witkos M, Fleshner NE, Sweet J, Evans A, Jewett MA, et al. Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: Implication on outcome J Urol 2006;176:979-84; discussion 984. |
|23.||Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-9. |